NYSE:ADCT   ADC Therapeutics SA
With an ADC platform validated by the FDA approval of ZYNLONTA® and a deep understanding of the oncology treatment landscape, ADCT is working to address significant unmet medical needs and improve outcomes for those with difficult-to-treat hematological cancers and solid tumors.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.